MX2016011114A - Composiciones y metodos para el tratamiento de tumores que sobreexpresan her2/neu. - Google Patents

Composiciones y metodos para el tratamiento de tumores que sobreexpresan her2/neu.

Info

Publication number
MX2016011114A
MX2016011114A MX2016011114A MX2016011114A MX2016011114A MX 2016011114 A MX2016011114 A MX 2016011114A MX 2016011114 A MX2016011114 A MX 2016011114A MX 2016011114 A MX2016011114 A MX 2016011114A MX 2016011114 A MX2016011114 A MX 2016011114A
Authority
MX
Mexico
Prior art keywords
her2
methods
compositions
treatment
expressing tumors
Prior art date
Application number
MX2016011114A
Other languages
English (en)
Inventor
Wallecha Anu
Shahabi Vafa
C Maciag Paulo
Paterson Yvonne
MASON Nicola
Seavey Matthew
Original Assignee
Advaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/189,008 external-priority patent/US20150366955A9/en
Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en
Application filed by Advaxis Inc filed Critical Advaxis Inc
Publication of MX2016011114A publication Critical patent/MX2016011114A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Esta invención proporciona composiciones y métodos para tratar y vacunar contra un tumor que expresa el antígeno HER2/neu e inducir una respuesta inmunitaria contra el mismo en un sujeto.
MX2016011114A 2014-02-25 2015-02-25 Composiciones y metodos para el tratamiento de tumores que sobreexpresan her2/neu. MX2016011114A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/189,008 US20150366955A9 (en) 2009-11-11 2014-02-25 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US14/268,436 US20140234370A1 (en) 2009-11-11 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US201462076411P 2014-11-06 2014-11-06
PCT/US2015/017559 WO2015130810A2 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors

Publications (1)

Publication Number Publication Date
MX2016011114A true MX2016011114A (es) 2017-02-20

Family

ID=54009773

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011114A MX2016011114A (es) 2014-02-25 2015-02-25 Composiciones y metodos para el tratamiento de tumores que sobreexpresan her2/neu.

Country Status (13)

Country Link
EP (1) EP3110942A4 (es)
JP (1) JP2017507943A (es)
KR (2) KR20160122829A (es)
CN (1) CN106661538A (es)
AU (1) AU2015223136A1 (es)
BR (1) BR112016019534A2 (es)
CA (1) CA2940646A1 (es)
IL (1) IL247436A0 (es)
MX (1) MX2016011114A (es)
NZ (1) NZ723750A (es)
RU (1) RU2016137834A (es)
SG (1) SG11201607036XA (es)
WO (1) WO2015130810A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
CN103687611A (zh) 2011-03-11 2014-03-26 阿德瓦希斯公司 基于李斯特菌属的佐剂
BR112014022662A2 (pt) 2012-03-12 2017-10-03 Advaxis Inc Inibição da função de célula supressora seguindo tratamento de vacina de listeria
EP3107566A4 (en) 2014-02-18 2017-10-11 Advaxis, Inc. Biomarker directed multi-target immunotherapy
CN106413745A (zh) * 2014-03-05 2017-02-15 阿德瓦希斯公司 用于提高效应t细胞与调节性t细胞的比率的方法和组合物
MA39849A (fr) 2014-04-24 2017-03-01 Advaxis Inc Souches de listeria utilisées comme vaccin recombinant et procédé de production
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
AU2016369519B2 (en) 2015-12-16 2023-04-20 Gritstone Bio, Inc. Neoantigen identification, manufacture, and use
WO2018102584A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
CN111356760A (zh) 2017-09-19 2020-06-30 阿德瓦希斯公司 细菌或李斯特菌菌株的冻干组合物和方法
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
JP2021503897A (ja) 2017-11-22 2021-02-15 グリットストーン オンコロジー インコーポレイテッド 新生抗原のためのジャンクションエピトープ提示の低減

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors

Also Published As

Publication number Publication date
WO2015130810A3 (en) 2016-01-28
SG11201607036XA (en) 2016-09-29
IL247436A0 (en) 2016-11-30
AU2015223136A1 (en) 2016-09-22
NZ723750A (en) 2024-02-23
WO2015130810A2 (en) 2015-09-03
EP3110942A2 (en) 2017-01-04
CA2940646A1 (en) 2015-09-03
EP3110942A4 (en) 2017-08-30
KR20160122829A (ko) 2016-10-24
CN106661538A (zh) 2017-05-10
BR112016019534A2 (pt) 2017-10-24
RU2016137834A (ru) 2018-03-29
JP2017507943A (ja) 2017-03-23
KR20240038103A (ko) 2024-03-22

Similar Documents

Publication Publication Date Title
MX2016011114A (es) Composiciones y metodos para el tratamiento de tumores que sobreexpresan her2/neu.
IL265755A (en) A chimeric antibody receptor for cancer therapy
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
IL260443B (en) Combinations of anti-egfr for cancer treatment
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
NZ731467A (en) Anti-tim3 antibodies and methods of use
IL263382A (en) Preparations and methods for vaccination against tumors and immunotherapy using HER2/NEU
NZ738008A (en) Tigit-binding agents and uses thereof
TN2016000559A1 (en) Monoclonal antibodies against her2 epitope and methods of use thereof
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
MX2017011246A (es) Composiciones a base de listeria que comprenden un sistema de expresion de minigen peptidico y metodos de uso de estas.
IL260935A (en) Methods for treating hrg, her2-, er breast cancer using combined treatments that include an anti-erbb3 antibody
HK1254404A1 (zh) 治療過度表達生長抑素受體的神經內分泌腫瘤的方法
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
IL265786A (en) Materials and methods for increasing radiotherapy against cancer
IL263562A (en) Methods and compositions for prostate cancer diagnosis and treatment
IL290130A (en) Treatment of insidious tumors in the immune system
PH12016501838A1 (en) Compounds and their methods of use
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX2019006694A (es) Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
ZA202204223B (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer
ZA201707117B (en) Antibody compositions for tumor treatment